An interventional study of Cannabidiol (CBD) and Placebo in Healthy Aging and Cognition, sponsored by Medical University of Silesia. Not yet recruiting. Open to participants aged 60 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Medical University of Silesia · Not applicable, Interventional, and Basic science
This pilot study aims to investigate the effects of a single oral dose of cannabidiol (CBD) on memory and attention in healthy adults aged 60 to 70 years. CBD is a naturally occurring compound found in cannabis that does not produce the intoxicating effects associated with THC.
The main research question is whether CBD can improve episodic memory (the ability to remember previously learned information), working memory (the ability to temporarily hold and use information), and attention compared with placebo.
The researchers hypothesize that participants will perform better on memory and attention tasks after receiving CBD than after receiving placebo.
The study will involve approximately 50 healthy adults aged 60 to 70 years. Each participant will attend two study sessions, scheduled 14 to 30 days apart. During one session, participants will receive a single oral dose of 25 mg CBD, while during the other session, they will receive a placebo capsule containing no CBD. The order of administration will be randomly assigned, and neither the participants nor the researchers assessing their performance will know which capsule was administered during each session.
Memory and attention will be evaluated using standardized memory tests and computer-based cognitive tasks. The findings will provide preliminary evidence on the potential effects of CBD on cognitive functioning in older adults.
Medical University of Silesia is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will receive CBD during the first study session and placebo during the second study session, following a washout period of 14-30 days.
Dietary Supplement: Cannabidiol (CBD) · Dietary Supplement: Placebo
This group will receive placebo during the first study session and CBD during the second study session, following a washout period of 14-30 days.
Dietary Supplement: Cannabidiol (CBD) · Dietary Supplement: Placebo
Single oral administration of a softgel capsule containing 25 mg of cannabidiol (CBD). Each participant will receive CBD during one of the two experimental sessions, according to the randomized treatment sequence.
Single oral administration of a placebo softgel capsule containing medium-chain triglyceride (MCT) oil only. The placebo capsules will be visually indistinguishable from the CBD capsules. Each participant will receive placebo during one of the two experimental sessions, according to the randomized treatment sequence.
Verbal Episodic Memory - RAVLT Delayed Free Recall
Verbal episodic memory will be assessed using the Rey Auditory Verbal Learning Test (RAVLT). Participants will be presented with a list of 15 unrelated words over five learning trials, followed by an interference list and delayed recall assessments. The outcome measure will be the number of correctly recalled words during the second delayed free recall assessment, approximately 120 minutes after administration of CBD or placebo. Scores range from 0 to 15, with higher scores indicating better memory performance.
Time frame: Approximately 120 minutes after administration of CBD or placebo, during each of the two study sessions.
Working Memory - 2-Back Task Accuracy
Working memory will be assessed using a computerized visual 2-back task with emotionally neutral stimuli. Participants will indicate whether the currently presented stimulus matches the stimulus presented two positions earlier. Performance will be measured as the percentage of correct responses, ranging from 0% to 100%, with higher scores indicating better working memory performance.
Time frame: During cognitive testing beginning approximately 120 minutes after administration of CBD or placebo, at each of the two study sessions.
Attention - 0-Back Task Accuracy
Attention will be assessed using a computerized visual 0-back task with emotionally neutral stimuli. Participants will respond to the presentation of a predefined target stimulus. Performance will be measured as the percentage of correct responses, ranging from 0% to 100%, with higher scores indicating better attention performance.
Time frame: During cognitive testing beginning approximately 120 minutes after administration of CBD or placebo, at each of the two study sessions.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
Medical University of Silesia →